Ultrasound Technology Developed at U-M Now in Clinical Trials for Liver Cancer

Trial will evaluate the safety and efficacy of histotripsy against liver tumors at eight U.S. sites.

5:00 AM

Author | Ian Demsky

Color wires Microsopic Tissue Ultrasonic waves
Illustration of histotripsy technology. Image courtesy of Medicine at Michigan Magazine.

The University of Michigan is one of eight sites around the country that will enroll patients in a clinical trial to evaluate the safety and efficacy of a technology that uses ultrasound to treat liver tumors.

The #HOPE4LIVER trial will employ the noninvasive technique to mechanically destroy primary and metastatic liver tumors.

The technology, called histotripsy, was developed by U-M researchers over more than 15 years and is being commercialized by a U-M startup company, HistoSonics, which is sponsoring the trial.

Using ultrasonic pulses is nothing new to medicine, but the process behind histotripsy is. While previous techniques use heat energy to ablate tissues, histotripsy harnesses the energy of thousands of microbubbles — called cavitation — to emulsify tissue. And it can do so with great precision, narrowly targeting the tissues of interest.

Interventional radiologist Mishal Mendiratta-Lala, M.D., who specializes in the diagnosis and treatment of liver cancer and other abdominal cancers, is principal investigator of the U-M trial site.

MORE FROM THE LAB: Subscribe to our weekly newsletter

"We are very excited to help move this technology out of the laboratory and into a clinical trial where we can evaluate its safety and efficacy for patients," she says. "Preclinical models have been very encouraging regarding the technology's ability not only to destroy tumors non-invasively, but also to stimulate the body's immune response to cancer."

As a researcher, Mendiratta-Lala has worked closely with one of the technology's principal inventors, Zhen Xu, Ph.D., a professor of biomedical engineering at U-M, to analyze histotripsy's impact in animal models of liver cancer.

We are very excited to help move this technology out of the laboratory and into a clinical trial where we can evaluate its safety and efficacy for patients.
Mishal Mendiratta-Lala, M.D.

HistoSonics is also conducting clinical trials of the technology in Europe and hopes to expand the use of its platform to other types of solid tumors after the U.S. liver study.

"Anyone close to the field of therapeutic ultrasound knows that the novel science of histotripsy was born from the work of an incredible team of researchers at U-M," says Mike Blue, HistoSonics' president and CEO. "It is only fitting that our collaborating U-M physicians and the hospital are a part of this trial and represent the science that that they discovered and developed alongside the company over the past decade. We could not be happier for everyone who has played a role in getting this platform to where it is today, especially the early inventors and company cofounders."

Meanwhile, histotripsy has also shown promise toward improving immunotherapy.

A study from the lab of U-M surgeon Clifford Cho, M.D., published last year in the Journal for ImmunoThearpy of Cancer, found histotripsy ablation magnified the effect of checkpoint inhibition immunotherapy in mouse models of melanoma and hepatocellular carcinoma.

Disclosures: U-M retains a financial stake in HistoSonics, as do a number of researchers who helped to develop the technology, and each stand to benefit financially from the success of the platform. Serving in the capacity of a paid consultant to the company, Cho is co-principal investigator of the national trial to treat liver tumors in humans; as one of the original researchers into the technology, he also has a financial interest in it.

Like Podcasts? Add the Michigan Medicine News Break on iTunes or anywhere you listen to podcasts.

More Articles About: Health Tech Cancer Research Liver Cancer Clinical Trials Cancer: Help, Diagnosis & Treatment
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]


Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Featured News & Stories cancer cell blue yellow
Health Lab
Less chemoradiation is possible for some cancer patients
Some oropharynx cancer patients may qualify for less radiation treatments, according to a new study from experts at the University of Michigan Health Rogel Cancer Center.
cancer cell blue yellow
Health Lab
Targeted drug shows promising ability in treating rare head and neck cancers
Experts at Rogel Cancer Center develop and study the impact of a new drug for salivary gland cancers
Health care provider with stethoscope holds patient's hand
Health Lab
Combatting prostate cancer stigma
Prostate cancer is highly treatable and over 98% of men survive 10 years if the cancer is diagnosed and treated early.
Woman in pink shirt lifts kettleball in an outdoor exercise class
Health Lab
How to make cancer prevention more equitable
Expert explains six behavioral risk factors for cancer and why current programs don’t always meet the needs of people from racially and ethnically minoritized groups and other vulnerable populations.
Illustration of a doctor and patient looking at ultrasound
Health Lab
Novel device detects cervix “ripening” to predict normal and abnormal labor
Multi-specialty team is studying a non-invasive method to measure underlying cervical tissue changes that precede birth with the hopes of predicting timing of birth.
Portrait of Max Wicha, founding director of Rogel Cancer Center
Health Lab
‘We might for the first time really be thinking of cures of cancer’
Founding Rogel Cancer Center Director reflects on how cancer evolved from ‘the least scientific discipline’ to a shining example of how basic research discoveries can change clinical care.